Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
NCT00242723 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1559
Last updated 2026-05-01
Summary
Background:
* Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.
* Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in patients.
* A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them.
Objectives:
* To evaluate people with cancer of the lung, pleura or esophagus for participation in NCI clinical trials.
* To obtain biopsies (small pieces of tissue) from tumor, normal tissue and blood samples to learn more about the cellular changes in blood and tissue in tumors of the lung, esophagus and pleura and surrounding structures in the chest.
Eligibility: Patients 2 years of age and older with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung. Note: Patients \>= 2 years of age and under 18 years of age may only participate in research sample collection.
Design:
* Up to 1310 patients may be included in this study.
* Patients undergo standard tests for evaluating the stage of their disease and for determining eligibility for an NCI investigational treatment study.
* All patients undergo bronchoscopy and bronchoalveolar lavage ("washing" with salt water) to assess their tumor and collect a sample of normal tissue. Patients whose tumor is located on the outside portion of the lung may also undergo thoracoscopy to obtain a tumor sample. For bronchoscopy and bronchoalveolar lavage a tube with a light is passed through the nose or mouth into the lungs to examine the airways. Salt water is injected through the tube and then withdrawn to obtain cells for laboratory studies. For the thoracoscopy a small tube with a light is put through a small hole in the chest to obtain the tumor sample. Both procedures are usually done under general anesthesia. The tissue is examined to identify cell characteristics of people who respond to certain therapies and to identify markers on the surface of the tissue that may be useful in future research and treatment.
* Blood and urine samples are collected from patients.
* Patients who are eligible for a treatment study at NCI are offered participation in the study.
* Patients for whom standard surgery, radiation or chemotherapy is more appropriate may receive treatment at NCI or with their own physician.
* Patients who receive treatment at NCI return for follow-up examinations 4 weeks after discharge and then every 2 to 4 months depending on the nature of their cancer.
Conditions
- Malignant Pleural Mesotheliomas NOS
- Esophageal Cancers NOS
- Lung Cancer NOS
- Thoracic Cancers
- Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
David S Schrump, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 2 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-11-09
Countries
- United States
Study Locations
More Related Trials
-
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
NCT07008664 ·Status: RECRUITING
-
Molecular Analysis of Thoracic Malignancies
NCT01385722 ·Status: ENROLLING_BY_INVITATION
-
Biology Studies of Hematologic Cancers
NCT00923442 ·Status: ENROLLING_BY_INVITATION
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
NCT00897117 ·Status: RECRUITING
-
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
NCT00899405 ·Status: RECRUITING
-
Detection of Tumor DNA in Blood Samples From Cancer Patients
NCT02288754 ·Status: UNKNOWN
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
NCT06482073 ·Status: RECRUITING
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
NCT02178163 ·Status: RECRUITING ·Phase: NA
-
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
NCT01503619 ·Status: COMPLETED
-
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT02279004 ·Status: ACTIVE_NOT_RECRUITING
-
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
NCT01433224 ·Status: COMPLETED
-
Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer
NCT00579462 ·Status: COMPLETED
-
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507
NCT00907699 ·Status: WITHDRAWN
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089 ·Status: RECRUITING
-
Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx
NCT00899340 ·Status: COMPLETED
-
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer
NCT00899782 ·Status: COMPLETED
-
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663 ·Status: COMPLETED
-
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
NCT00897650 ·Status: COMPLETED
-
Nuclear Matrix and Cancer: Proteomic and Genomic Analyses Using Microarray in Cells Obtained Via Thoracocentesis
NCT01284777 ·Status: COMPLETED
-
Clinical and Laboratory Analysis of Familial Cancer
NCT02565004 ·Status: COMPLETED
-
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
NCT00898313 ·Status: RECRUITING
-
DNA Repair and Genetic Susceptibility to Lung Cancer
NCT00611598 ·Status: COMPLETED
-
DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer
NCT00339859 ·Status: COMPLETED
-
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
NCT05530759 ·Status: RECRUITING
-
Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection
NCT06895551 ·Status: COMPLETED